CTC AR-V7 Assay Shows Promise as Treatment Guide in mCRPC
An assay for nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified patients with metastatic castration-resistant prostate cancer who had better outcomes from treatment with taxanes, and those did better with androgen receptor-signaling inhibitors.
Source: OncLive